Cancer therapy-related complications in the bowel and mesentery: an imaging perspective

[1]  A. Hara,et al.  Imaging of Drug-induced Complications in the Gastrointestinal System. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  L. Brandt,et al.  Update on Colon Ischemia: Recent Insights and Advances , 2015, Current Gastroenterology Reports.

[3]  C. Lall,et al.  Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective , 2015, Insights into Imaging.

[4]  R. Lamba,et al.  Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective , 2015, Insights into Imaging.

[5]  Yoonjin Cho,et al.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.

[6]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[8]  Yang Yao,et al.  Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. , 2014, Critical reviews in oncology/hematology.

[9]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[10]  Sung-Bae Kim,et al.  Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Janjigian,et al.  Distinguishing benign and life-threatening pneumatosis intestinalis in patients with cancer by CT imaging features. , 2013, AJR. American journal of roentgenology.

[12]  T. Adar,et al.  Images in clinical medicine. Pneumatosis intestinalis. , 2013, The New England journal of medicine.

[13]  A. Lev-Toaff,et al.  Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients , 2013, Abdominal Imaging.

[14]  K. Rolston,et al.  Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Silverman,et al.  Complications of oncologic therapy in the abdomen and pelvis: a review , 2013, Abdominal Imaging.

[16]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Yen,et al.  Images in clinical medicine. Pneumatosis cystoides intestinalis. , 2011, The New England journal of medicine.

[18]  G. Coukos,et al.  Clinical predictors of bevacizumab-associated gastrointestinal perforation. , 2011, Gynecologic oncology.

[19]  B. Barlogie,et al.  Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients , 2011, Cancer.

[20]  A. Allen,et al.  Cardiac mass in a rapidly deteriorating patient. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[22]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[23]  G. Scambia,et al.  Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature , 2010, Obstetrics and gynecology international.

[24]  L. Paz-Ares,et al.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  M. Bamat,et al.  Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose. , 2010 .

[26]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[27]  V. Georgoulias,et al.  Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Bruzzi,et al.  Imaging of the gastrointestinal complications of systemic chemotherapy. , 2009, Clinical radiology.

[29]  Shenhong Wu,et al.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.

[30]  Sarah M Gressett,et al.  Intricacies of Bevacizumab-Induced Toxicities and Their Management , 2009, The Annals of pharmacotherapy.

[31]  X. Pivot,et al.  A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Pollock,et al.  Challenges in Surgical Management of Abdominal Pain in the Neutropenic Cancer Patient , 2008, Annals of surgery.

[33]  H. Sawaf,et al.  Radiologic findings in taxane induced colitis. , 2008, European journal of radiology.

[34]  N. Wolmark,et al.  Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin , 2007, Cancer.

[35]  E. Paulson,et al.  Pneumatosis intestinalis in the adult: benign to life-threatening causes. , 2007, AJR. American journal of roentgenology.

[36]  T. Smyrk,et al.  Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  B. Monk,et al.  What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? , 2007, Gynecologic oncology.

[38]  R. Thoeni,et al.  CT imaging of colitis. , 2006, Radiology.

[39]  A. Winterbottom,et al.  The CT appearances of sclerosing mesenteritis and associated diseases. , 2006, Clinical radiology.

[40]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Daohai Yu,et al.  Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Sauerbruch,et al.  Neutropenic enterocolitis in adults: systematic analysis of evidence quality , 2005, European journal of haematology.

[43]  E. Kotter,et al.  MR findings in a rare case of sclerosing mesenteritis of the mesocolon , 2005, Journal of magnetic resonance imaging : JMRI.

[44]  M. Hidalgo,et al.  Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) , 2004, Clinical Cancer Research.

[45]  M. Dimopoulos,et al.  Adverse effects of thalidomide administration in patients with neoplastic diseases. , 2004, The American journal of medicine.

[46]  G. Hortobagyi,et al.  Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy , 2004, Cancer.

[47]  M. Cappell.  Colonic Toxicity of Administered Drugs and Chemicals , 2004, American Journal of Gastroenterology.

[48]  D. Schwartzentruber,et al.  Gastrointestinal Perforations Associated With Interleukin-2 Administration , 2004, Journal of immunotherapy.

[49]  F. Mandelli,et al.  Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma , 2004, Annals of Hematology.

[50]  K. Horton,et al.  CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[51]  H. Greenberg,et al.  Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. , 2003, Radiology.

[52]  C. Fuchs,et al.  Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Candelaria,et al.  Gastrointestinal pneumatosis after docetaxel chemotherapy. , 2002, Journal of clinical gastroenterology.

[54]  O. Sezer,et al.  Colitis associated with docetaxel-based chemotherapy , 2000, The Lancet.

[55]  N. Gourtsoyiannis,et al.  CT evaluation of mesenteric panniculitis: prevalence and associated diseases. , 2000, AJR. American journal of roentgenology.

[56]  K. Horton,et al.  Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[57]  N. Harbeck,et al.  Thrombophilic State in Breast Cancer , 1999, Seminars in thrombosis and hemostasis.

[58]  R. Barakat,et al.  Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. , 1998, Gynecologic oncology.

[59]  G. Vassal,et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Hecht.  Gastrointestinal toxicity or irinotecan. , 1998, Oncology.

[61]  J. Cain,et al.  A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. , 1997, Gynecologic oncology.

[62]  T. Kawarabayashi,et al.  Clostridium difficileColitis Associated with Cisplatin-Based Chemotherapy in Ovarian Cancer Patients , 1996 .

[63]  R. Haggitt,et al.  Pneumatosis intestinalis: a review. , 1995, The American journal of gastroenterology.

[64]  M. Piver,et al.  Intestinal perforation secondary to paclitaxel. , 1995, Gynecologic oncology.

[65]  Hohneker Ja.  A summary of vinorelbine (Navelbine) safety data from North American clinical trials. , 1994 .

[66]  S. Kaste,et al.  Typhlitis in children with cancer: a 30-year experience. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  Hung-Ming Wang,et al.  Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Report of four cases combining 5‐fluorouracil infusion and cisplatin with antiemetics dexamethasone , 1993, Cancer.

[68]  M. Mosseri,et al.  In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. , 1993, Cancer research.

[69]  A. Davidoff,et al.  Pneumatosis Intestinalis: Surgical Management and Clinical Outcome , 1990, Annals of surgery.

[70]  T. Kuzel,et al.  Thrombogenicity of intravenous 5‐fluorouracil alone or in combination with cisplatin , 1990, Cancer.

[71]  R. Sharma.  Vincristine and gastrointestinal transit. , 1988, Gastroenterology.

[72]  N. Petrelli,et al.  Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  N. Petrelli,et al.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Hainsworth,et al.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. , 1986, Annals of internal medicine.

[75]  P. Meyers,et al.  Bowel perforation during initial treatment for childhood non‐Hodgkin's lymphoma , 1985, Cancer.

[76]  J. Jamart.  Pneumatosis cystoides intestinalis. A statistical study of 919 cases. , 1979, Acta hepato-gastroenterologica.

[77]  D Grob,et al.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases. , 1973, Cancer research.

[78]  P. Toghill,et al.  Death from paralytic ileus following vincristine therapy. , 1970, Postgraduate medical journal.

[79]  C. Santillan.  Computed tomography of small bowel obstruction. , 2013, Radiologic clinics of North America.

[80]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .

[81]  L. Ellis,et al.  Management of bevacizumab-associated bowel perforation: a case series and review of the literature. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  M. Camilleri,et al.  Audit of suspected chronic intestinal pseudo-obstruction in patients with gynecologic cancer. , 2008, European Journal of Gynaecological Oncology.

[83]  S. Rosenberg,et al.  Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. , 2007, Journal of immunotherapy.

[84]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[85]  K. Kume,et al.  Ischemic Colitis Associated With Paclitaxel and Carboplatin Chemotherapy , 2003, American Journal of Gastroenterology.

[86]  C. Valls.  Fat-ring sign in sclerosing mesenteritis. , 2000, AJR. American journal of roentgenology.

[87]  T. Kawarabayashi,et al.  Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. , 1996, Gynecologic oncology.

[88]  R. Allerton.  Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[89]  J. Hohneker.  A summary of vinorelbine (Navelbine) safety data from North American clinical trials. , 1994, Seminars in oncology.

[90]  J. Lokich,et al.  Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. , 1986, AJR. American journal of roentgenology.

[91]  C. Moertel,et al.  Mesenteric lipodystrophy. , 1974, Annals of internal medicine.

[92]  G. Botta,et al.  Retractile mesenteritis. , 1962, The New England journal of medicine.